Several studies have shown the relation between @entity2743 and @entity850 /occlusion of intracranial arteries. To our knowledge, only 31 cases, including our case, of concurrent @entity2743 or @entity7244 /occlusion have been described. The @entity1 were predominantly @entity1 , and their ages ranged from 10 to 54  years (mean, 29.3  years). Transient @entity63 attacks and @entity385 were the common symptoms in these @entity1 . Except one previous case and the present case, all cases showed @entity3935 when the cerebral @entity63 event occurred. Among the 29 cases, in which the treatment regimen was known, antithyroid therapy was administered in 25 cases, and surgical treatment for @entity6249 was performed in 11 cases. Most of the @entity1 eventually recovered from the neurological symptoms after medical and/or surgical treatment; one of the @entity1 died, and one @entity1 's condition worsened. Although the mechanism underlying intracranial @entity432 or @entity850 in @entity1 with @entity2743 has not been elucidated, several hypotheses have been described. Thyroid hormones may augment vascular sensitivity to the sympathetic nervous system and induce pathological changes in the arterial walls. An immune-mediated mechanism may play a role in the pathogenesis of these diseases. @entity731 may be associated with these disorders. @entity1333 induced by antithyroid drugs may cause changes in the intracranial arteries. Finally, the possibility of a mere coincidence of @entity2743 and these vascular changes should also be considered. Cerebrovascular hemodynamic changes induced by @entity2743 were considered to be responsible for the cerebral @entity63 events. Excessive thyroid hormone production is considered to increase the cerebral metabolism and @entity26 consumption. In addition, @entity2743 -induced @entity49 may influence @entity63 events. Therefore, the possibility of @entity2743 should be considered when @entity1 with @entity2743 show exacerbation of @entity2806 at follow-up. The necessity of surgery in addition to antithyroid therapy might be dependent on the mechanisms of the vascular changes and symptoms. If @entity1378 is associated with vascular changes and symptoms, antithyroid therapy may be adequate. However, if immune-mediated mechanisms or coincidences are considered to be associated with vascular changes and symptoms, like our case, surgical procedures might be needed.

Concurrent @entity2743 and XXXX /occlusion: special considerations regarding the state of thyroid function, etiology, and treatment.

@entity1 :: ('9606', 'Species') :: ['women', 'patients', 'patient'] @entity3935 :: ('MESH:D013958', 'Disease') :: ['thyrotoxicity'] @entity6249 :: ('MESH:D059345', 'Disease') :: ['cerebral vessel diseases'] @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemic'] @entity2743 :: ('MESH:D006111', 'Disease') :: ["Graves' disease and moyamoya syndrome", "Graves' disease", 'thyrotoxicosis'] @entity1333 :: ('MESH:D014657', 'Disease') :: ['Vasculitis'] @entity26 :: ('MESH:D010100', 'Chemical') :: ['oxygen'] @entity2806 :: ('MESH:D002545', 'Disease') :: ['cerebral ischemic symptoms'] @entity7244 :: ('MESH:D020765', 'Disease') :: ['intracranial arterial stenosis'] @entity49 :: ('MESH:D019851', 'Disease') :: ['hypercoagulability'] @entity1378 :: ('MESH:D006980', 'Disease') :: ['hyperthyroidism'] @entity432 :: ('MESH:D001157', 'Disease') :: ['arterial occlusion'] @entity731 :: ('MESH:D050197', 'Disease') :: ['Atherosclerosis'] @entity850 :: ('MESH:D003251', 'Disease') :: ['stenosis'] @entity385 :: ('MESH:D002544', 'Disease') :: ['cerebral infarction']
@entity7244 :: (MESH:D020765,Disease) :: ['intracranial arterial stenosis']
